Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$1.3 million.

  • C4 Therapeutics' Change in Accured Expenses fell 148.30% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year decrease of 6805.00%. This contributed to the annual value of -$1.3 million for FY2024, which is 196.28% down from last year.
  • As of FY2024, C4 Therapeutics' Change in Accured Expenses stood at -$1.3 million, which was down 196.28% from $1.3 million recorded in FY2023.
  • C4 Therapeutics' Change in Accured Expenses' 5-year high stood at $5.1 million during FY2022, with a 5-year trough of -$1.3 million in FY2024.
  • Over the past 3 years, C4 Therapeutics' median Change in Accured Expenses value was $1.3 million (recorded in 2023), while the average stood at $1.7 million.
  • In the last 5 years, C4 Therapeutics' Change in Accured Expenses surged by 71.11% in 2021 and then tumbled by 196.28% in 2024.
  • Yearly analysis of 5 years shows C4 Therapeutics' Change in Accured Expenses stood at $2.6 million in 2020, then spiked by 71.11% to $4.4 million in 2021, then grew by 16.13% to $5.1 million in 2022, then tumbled by 74.11% to $1.3 million in 2023, then tumbled by 196.28% to -$1.3 million in 2024.